ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
11 announcements with these filters
Nidan Laboratories and Healthcare Limited will hold its 26th Annual General Meeting on September 28, 2026. The company has submitted its Annual Report for FY 2025-26.
Nidan Laboratories and Healthcare Limited will convene its 26th Annual General Meeting on September 28, 2026. The board also approved book closure and e-voting schedules.
Nidan Laboratories and Healthcare Limited has scheduled a board meeting for August 20, 2026. The meeting agenda covers general business matters.
Nidan Laboratories approved FY26 audited financial results and re-appointed independent directors and statutory auditors. These board decisions ensure operational continuity and regulatory compliance.
Nidan Laboratories re-appointed Nilesh Bide and Abhinay Nerurkar as Independent Directors for five-year terms. These appointments ensure continued board stability and regulatory compliance.
Nidan Laboratories And Healthcare Ltd reported revenue from operations of ₹12.4 Cr (-11.4% YoY) and net profit of ₹0.1 Cr (-88.9% YoY) for H2 FY26.
Nidan Laboratories reported total income of ₹27.40 Crore for FY26. The board also approved the re-appointment of two independent directors and its statutory auditors.
Nidan Laboratories and Healthcare Limited received a SEBI Show Cause Notice alleging mis-utilization of ₹29.99 Crore from its ₹50 Crore IPO proceeds. The regulator is investigating deviations from prospectus disclosures during FY 2021-2024. The financial impact is currently undetermined as proceedings are at the notice stage.
Nidan Laboratories and Healthcare Limited submitted its Structural Digital Database (SDD) Compliance Certificate for the financial year ended March 31, 2026. The certificate, issued by M S Jog & Associates, confirms the company maintains a non-tamperable database to track UPSI events as required under SEBI PIT Regulations.
Nidan Laboratories and Healthcare Limited submitted the compliance certificate under SEBI (Depositories and Participants) Regulations for the quarter ended March 31, 2026. The registrar, Bigshare Services, confirmed that share certificates received for dematerialisation were processed and cancelled within prescribed timelines.
Nidan Laboratories and Healthcare Limited notified the NSE regarding the non-applicability of Regulation 24A of SEBI LODR. As an SME-listed entity, the company is exempt from submitting an Annual Secretarial Compliance Report. The company confirmed it remains compliant with all other applicable listing regulations.